“Peijia Medical” was established in early 2012, by returned oversea Chinese expert in professional medical device industry, providing R&D and production of interventional medical products. Peijia Medical is dedicated to research, production and sales of high-end medical device for heart valve disease treatment. The core technical team came from famous international and domestic companies in related industry, with valuable experience in innovation, R&D, quality system, production and sales management. The achievements include the success launches of the first domestic heart drug eluting stent and the first domestic intracranial embolization coil.
Location: China
Investors 3
| Date | Name | Website |
| - | Grand Flig... | gfinvestme... |
| - | SDIC Fund ... | sdicfund.c... |
| 09.02.2022 | Matrix Par... | matrixpart... |
Mentions in press and media 17
| Date | Title | Description |
| 26.03.2026 | Peijia Medical Announces 2025 Annual Results | SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the yea... |
| 18.03.2026 | DCwire® Micro Guidewire Receives FDA 510(k) Clearance, Marking a Key Milestone in Peijia Medical's Global Expansion | SUZHOU, China, March 18, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its DCwire® Micro Guidewi... |
| 09.02.2026 | Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System | HONG KONG, Feb. 9, 2026 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed G... |
| 25.08.2025 | Peijia Medical Announces 2025 Interim Results | HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months... |
| 01.04.2025 | Peijia Medical collaborates with dsm-firmenich to create groundbreaking innovative medical device products | SUZHOU, China, April 1, 2025 /PRNewswire/ -- Today, April 1st, Peijia Medical Technology (Suzhou) Co., Ltd. held a strategic innovation cooperation signing ceremony and a press conference to announce the research and development achievement... |
| 26.03.2025 | Peijia Medical Announces 2024 Annual Results | HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year ende... |
| 29.08.2024 | Peijia Medical's Strong Growth in 2024: A Deep Dive into Interim Results | Peijia Medical, a prominent player in China's medical device market, has unveiled its interim results for the first half of 2024. The numbers tell a compelling story of growth, resilience, and strategic execution. With a sharp focus on tran... |
| 28.08.2024 | Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical | SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiar... |
| 26.08.2024 | Peijia Medical Announces 2024 Interim Results | HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six month... |
| 26.08.2024 | Peijia Medical Announces 2024 Interim Results | HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six month... |
Show more